About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Characteristics of Empagliflozin Initiators | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT03050619

Characteristics of Empagliflozin Initiators

Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in thei...

Lead sponsor: Boehringer Ingelheim•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Boehringer Ingelheim

Collaborators

Eli Lilly and Company

Study Design: cross sectional

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All patients will be required to meet all of the following criteria:
•At least 12 months of continuous registration prior to the index date in a practice contributing up to standard (UTS) data to the Clinical Practice Research Datalink (CPRD). Infants younger than 1 year will not be required to have 12 months of continuous UTS registration in the CPRD.
•A new user of one of the index prescriptions (empagliflozin, other SGLT2 inhibitor, or non-insulin GLDs) or a fixed dose combination (FDC) with metformin.

Exclusion Criteria

•There is no exclusion criterion in this study.

Related studies

Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on the Prevention of Type 2 Diabetes

NCT07659535 · Type 2 Diabetes

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more

RECRUITINGPhase 3

Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

NCT07581145 · Foot Ulcer Due to Type 2 Diabetes Mellitus

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight

Effectiveness of and Implementation Strategies for 'Disfrutando'.

NCT07023406 · Type 2 Diabetes Mellitus (T2DM)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 25, 2019Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment31,908

Start dateSep 2016

Last updatedJan 25, 2019

Condition

Type 2 Diabetes

Locations shown

Boehringer Ingelheim Investigational Site

Ingelheim

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 25, 2019Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions